Tango Therapeutics, Inc.
TNGX
$6.61
$0.111.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.18M | 5.39M | 4.12M | 11.61M | 19.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.18M | 5.39M | 4.12M | 11.61M | 19.88M |
| Cost of Revenue | 32.81M | 36.44M | 33.94M | 33.26M | 38.65M |
| Gross Profit | -29.63M | -31.05M | -29.82M | -21.66M | -18.78M |
| SG&A Expenses | 11.34M | 11.48M | 11.09M | 11.22M | 10.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.15M | 47.92M | 45.03M | 44.49M | 49.43M |
| Operating Income | -40.97M | -42.53M | -40.91M | -32.88M | -29.55M |
| Income Before Tax | -38.82M | -39.84M | -37.62M | -29.11M | -25.49M |
| Income Tax Expenses | 35.00K | 34.00K | 49.00K | 54.00K | 65.00K |
| Earnings from Continuing Operations | -38.85M | -39.88M | -37.67M | -29.17M | -25.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.85M | -39.88M | -37.67M | -29.17M | -25.55M |
| EBIT | -40.97M | -42.53M | -40.91M | -32.88M | -29.55M |
| EBITDA | -40.34M | -41.91M | -40.29M | -32.26M | -28.92M |
| EPS Basic | -0.35 | -0.36 | -0.35 | -0.27 | -0.24 |
| Normalized Basic EPS | -0.22 | -0.23 | -0.19 | -0.17 | -0.15 |
| EPS Diluted | -0.35 | -0.36 | -0.35 | -0.27 | -0.24 |
| Normalized Diluted EPS | -0.22 | -0.23 | -0.19 | -0.17 | -0.15 |
| Average Basic Shares Outstanding | 110.54M | 110.30M | 108.68M | 108.51M | 108.31M |
| Average Diluted Shares Outstanding | 110.54M | 110.30M | 108.68M | 108.51M | 108.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |